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Pharmacological cognitive enhancement (PCE), the use of illicit and/or prescription
drugs to increase cognitive performance, has spurred controversial discussion in
bioethics. In a semi-structured interview study with 60 German university students
and employees, differences and similarities in moral attitudes toward PCE among
30 experienced participants (EPs) vs. 30 inexperienced participants (IPs) were
investigated. Substances EPs used most often are methylphenidate, amphetamines,
tetrahydrocannabinol and modafinil. Both EPs and IPs addressed topics such as
autonomous decision making or issues related to fairness such as equality in test
evaluation and distortion of competition. While most EPs and IPs were convinced that
the decision of whether or not to use PCE is part of their individual freedom, their views
varied considerably with regard to fairness. IPs considered issues related to fairness as
much more critical than EPs. Thus, a person’s moral attitudes toward PCE may not only
depend on moral common sense, but also on whether they have used illegal and/or
prescription drugs for PCE before. This points to the importance of including the various
relevant stakeholder perspectives in debates on the ethical and social implications of
PCE.
Keywords: autonomy, distortion of competition, ethics, fairness, interview study, pharmacological cognitive
enhancement, stimulants
INTRODUCTION
Pharmacological cognitive enhancement (PCE), the use of illicit substances and/or prescription
drugs (off-label use) to improve cognitive performance, has become an often-discussed topic in
bioethics over the last decade (Schelle et al., 2014: p. 1; Garasic and Lavazza, 2016: p. 1; Schleim
and Quednow, 2018). The use of PCEs in students and employees has been reported in several
German surveys (Dietz, 2011; Franke et al., 2013; DAK, 2015). In general, the off-label use of
prescription drugs and/or the use of illicit drugs is considered more problematic than the use of
coffee or over the counter drugs such as caffeine, ginkgo or nicotine. Substances that have been
consumed for PCE are psychostimulants, antidementia drugs, and antidepressants, among others
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(Metzinger, 2012: 38; see, for example, Mache et al., 2012; Franke
et al., 2014). Besides the discussion whether these substances
have any objective detectable cognition enhancing effects on users
(Repantis et al., 2010: p. 475–480; Farah et al., 2014: p. 97–100),
there are normative concerns on the use of PCE (Schelle et al.,
2014; Faber et al., 2016; Garasic and Lavazza, 2016; O’Connor
and Nagel, 2017). A number of studies have investigated attitudes
toward PCE (Babcock and Byrne, 2000; Franke et al., 2012a,b;
Partridge et al., 2012; Bell et al., 2013; Sattler et al., 2013; Vrecko,
2013; Singh et al., 2014; Maier et al., 2015; Ram et al., 2017;
Vagwala et al., 2017).
The aim of this interview study was to find out what moral
attitudes toward pharmacological enhancement participants with
PCE experience (experienced participants, EPs) and without
PCE experience (inexperienced participants, IPs) are aware of
and whether those vary between the two groups. In this, the
term “moral attitude” refers to the moral “evaluation of an
object, concept, or behavior along a dimension of favor or
disfavor, good or bad, like or dislike” (Ajzen and Fishbein, 2000:
p. 3). Here, we focus on autonomy, fairness related aspects
(equality in test evaluation and distortion of competition) and
motivations to use PCE. The findings give an insight into
the differences between the views of EPs and IPs by directly
comparing them.
METHODS
Semi-structured interviews were performed at the University of
Mainz in 2015–2016. From January 2015 on, following approval
from the local Ethics Committee of the Landesaerztekammer
Rhineland-Palatinate, participants were recruited by flyers
posted in public places such as the university, supermarkets,
pharmacies and local firms, on the internet, and with support
of the Gutenberg Brain Study in Mainz. Incentives were
offered for participation (in the first phase of the recruitment
25€, in the second phase 50€). The recruitment process
received a limited response, and more students responded
than other groups. We explain this by the sensitivity of
the topic, especially in professional context. We interviewed
60 people. 30 were experienced with PCE, 30 were not.
Participants were aged 18–45 years (mean age = 26,93,
SD = 6,11), 45% [n = 27] were female, 68,3% [n = 41]
were students. Substances used by EPs were methylphenidate
(n = 21), (meth-)amphetamines (n = 14), tetrahydrocannabinol
(n = 3), modafinil (n = 2), anti-dementia drugs (n = 1),
ß-blockers (n = 1), cocaine (n = 1), ephedrine (n = 1).
Some EPs (n = 8) used more than one substance for
PCE.
Experienced participants and IPs were matched according
to age and gender. By EP, people were categorized who
have used or still were using illicit substances and/or
prescription drugs (off-label use) for cognitive enhancement.
By IP, people were categorized who have never used illicit
substances and/or prescription drugs (off-label use) for
PCE. The use of illicit drugs exclusively in a spare time
context did not lead to an exclusion from the IP group,
since PCE was defined as substance use for cognitive
enhancement only. To exclude self-medication, diagnoses
of psychiatric disorders treated with substances that also
could be used for PCE, led to an exclusion from the
study. A psychological SCID Interview (Structured Clinical
Interview for DSM-IV) was conducted with the participants
first. Persons diagnosed with potential anxiety disorders
or other during the SCID Interview were excluded from
the study. People who had been diagnosed with attention
deficit hyperactivity disorder (ADHD), depression or anxiety
disorder in their medical history were also excluded. Lifetime
diagnoses were hypothesized to avoid the possibility of
self-medication. Although it is possible that people treated
with prescription drugs modify the doses to enhance their
performance, it would have been almost impossible for us
to decide whether this was treatment or enhancement. For
this reason, we excluded persons with the above-named
diagnoses.
Five interviewers were trained to interview the participants.
The interviews took place in a separate room with one
interviewer talking to one participant. They were recorded with
voice recorders and transcribed, all data was pseudonymized.
The transcribed interviews were coded independently by SP
and HB with MAXQDA 12.0.2, according to the Grounded
Theory approach (Strauss and Corbin, 1990; Bryant and
Charmaz, 2010). Differences in coding were discussed
and agreed upon in open discourse. This was necessary
in rare cases when answers were imprecise. The aspects
presented in this paper were coded uniformly by both
coders.
Concerning moral aspects of PCE use, the following open
questions were asked: Do you think there are general reasons
speaking for the use of PCE? Do you think there are ethical
or moral reasons speaking for the use of PCE? Do you think
there are general reasons speaking against PCE? Do you think
there are ethical or moral reasons speaking against PCE? Do
you think the use of PCE is fair? Does PCE lead to distortion





According to Christman (2015), the concept of autonomy
is “generally understood to refer to the capacity to be one’s
own person, to live one’s life according to reasons and
motives that are taken as one’s own and not the product
of manipulative or distorting external forces.” Amongst
other aspects, it “concerns the freedom to decide what to
believe in and to weigh the pros and cons of a given course
of action” (Garasic and Lavazza, 2016: p. 4). Following
this understanding, participants’ statements concerning
whether or not individuals should be free to use PCE
were categorized as statements concerning autonomous
decision-making.
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Almost two-thirds of the participants [n = 37] came up with
autonomy-related aspects. 11 EPs and 14 in the IP group claimed
people should decide autonomously to use/disuse PCE. In either
group only one participant did not agree.
A typical EP opinion was:
“I think the moral aspect is massively overrated, in the end it
is a question everyone has to decide for themselves. It is part of
individual freedom to use such possibilities. After, of course, having
dealt with the risks.”
Experienced participants typically argued in favor of
autonomous decision-making: Individuals should be free
to decide whether they want to use PCE to enhance their
performance. They argued individuals should inform themselves
about risks related to PCE, such as side effects or risks of
addiction. Most of the IPs shared the EPs’ opinion that everyone
should be free to use or disuse PCE.
A typical IP opinion was:
“[A]s long as I do not harm anyone but myself, [...] I believe
everyone should consume, what they want. Also marihuana and,
for all I care, even Ritalin, if they need it once in a while. I guess
everyone knows, has to know, what they are doing to their body.”
Inexperienced participants highlighted the necessity of being
well informed. Users then would have to calculate risks and
expected benefits. Afterward they could decide if they were
willing to take the risks that might possibly occur.
Fairness
Statements concerning fairness, equality, and distortion of
competition were categorized under fairness. Almost two-thirds
of the EPs [n = 18] did not think it was unfair to use PCE
to enhance their performance, few [n = 2] found it rather not
unfair. Some [n = 4] said, it was unfair, few [n = 2] said it
was rather unfair. Few EPs [n = 3] thought that fairness was
not even a factor in PCE for they did not believe being in a
competition. IPs’ views on fairness were contrary: Almost half of
them [n = 13] thought of PCE as unfair, only few [n = 3] said it
was not unfair. Some [n = 4] were undecided, one fifth [n = 6] did
not comment. EPs were more likely to consider their behavior
as not unfair, whereas most IPs shared the view that PCE was
unfair.
In respect of the difficulty of clarifying the various meanings
of fairness (Schelle et al., 2014: p. 8), findings were divided
into different aspects of fairness: equality in test evaluation and
distortion of competition.
A typical EP answer was:
“I think, it’s not [unfair], because everyone has the choice, and
because I am not better than someone who deserved their top grade,
I never got the top grade with it [using PCE]. I would say, it just
helps me to deal with this monster called revision and exams better.”
With regard to the achievements that can be made with
support of PCE, this EP argued that only one defined best grade
can be realized in an exam. Since nobody could do better, the EP
believed PCE not to be unfair. Some of the EPs said they used
PCE primarily to get through the learning phase and to pass the
test:
“When I am in an exam situation [. . .], then I don’t take the exam
to be better than the others, but to show that I studied and, of course,
to pass the exam. I don’t think I am in competition with others.”
They do not think PCE is unfair because they do not use it to
outperform others, but to cope with learning struggles.
IPs saw this differently:
“It’s unfair in the sense that [. . .] you are better than the others,
better than your peers.”
Other than the EPs, most IPs believed that users would
perform better than those who did not use performance
enhancers. In consequence, they were convinced it was unfair to
use PCE in competitive situations.
Opinions on noticeable effects of PCE on users’ performance
that negatively influence conditions in competitive contexts were
categorized as distortion of competition. Almost half of the EPs
[n = 14] believed that there was no distortion of competition
between users and non-users in test situations, some [n = 8]
believed, it was. In contrast, almost half of the IPs [n = 14] said,
distortion of competition was given if users and non-users were
compared to each other, only a few [n = 3] did not think so.
Some participants referred to differences in individuals’
mental abilities and believed enhancement could lead to more
equality by closing the gap between people with lower and
higher cognitive abilities. One EP said too few people were using
enhancement to seriously distort competition in society.
Some IPs shared the opinion that PCE does not lead to
distortion of competition because users had to recover from using
PCE:
“I don’t think [it is a distortion of competition] because it will
balance out overall. The people who study for 3 days in a row then
have to sleep for 3 days afterward. I think they just shoot themselves
in the foot with it.”
However, typically IPs in this study believed distortion of
competition was caused, assuming users were in a better position
competitively than those not using PCE:
“[I]f you really use it for enhancement, then the performance will
accordingly be better. [...] Not, because the person is really better,
but because they took the stimulant drug in that moment.”
They were convinced PCE had noticeable effects that lead to
better performance in test situations.
AGREEING ON AUTONOMY,
DISAGREEING ON FAIRNESS
Most of the participants mentioned autonomy-related aspects
and thought that individuals should be free to decide on whether
or not to use PCE substances, similar to the results of Bell et al.
(2013) and Forlini and Racine (2009), but in contrast to a prior
interview study (Franke et al., 2012b) in which aspects related
to autonomous decision-making did not play an essential role.
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How can the differences in fairness-related moral attitudes be
explained, if EPs and IPs think that autonomy is important?
According to the interviews, EPs aimed for enhancing their
learning skills, staying awake longer or just passing a test or
exam. None of them aimed to enhance their abilities beyond
normal human capabilities. Most of them used PCE whilst
learning. They perceived a positive effect using PCE substances
but seemed to believe this effect only has an impact on their
own performance and was not a disadvantage for third persons.
When it comes to fairness, a clear majority of the EPs said it
was not unfair to enhance performance with PCE substances,
whereas a majority of IPs said it was unfair. This discrepancy
could possibly be explained by the EPs’ belief that using PCE
does not affect others: If there are no effects on third parties,
there is no moral reason to limit one’s autonomy. Another
possible interpretation for these findings is that PCE can be
considered a procedure people undergo who want to keep up
with their environment and who do not want to be left behind
in certain situations (Franke et al., 2012a; Sattler et al., 2013;
Forlini and Hall, 2016: p. 3).
Most IPs, on the other hand, were convinced that there
was a detectable effect on the results of tests or likewise
and therefore believed distortion of competition takes place.
Coherently they had the opinion that it is unfair to use
substances in such competitive situations. The IPs’ views are
in accordance with a study by Faber et al. (2016) who
discussed the unacceptability of PCE in laypeople against
the background of the Unfairness-Undeservingness Model
and the Hollowness-Undeservingness Model: “The Unfairness-
Undeservingness Model holds that people judge PCE to
be unacceptable because they take it to produce unfairness
and to undermine the degree to which PCE-users deserve
reward. The Hollowness-Undeservingness Model assumes that
people judge PCE to be unacceptable because they find
achievements realized while using PCE hollow and undeserved.”
(Faber et al., 2016: p. 1).
In addition, the views toward fairness expressed by EPs
might be interpreted against the background of the use of
prescription and/or illicit drugs for PCE not being commonly
accepted in society. The awareness of a negative public
attitude toward PCE may lead EPs to justify themselves for
using PCE. A strategy like this can be seen as being in
line with a framework presented by Shalvi et al. (2015),
according to which self-serving justification processes may
allow people to engage in moderate unethical behavior and
still feel moral about it. If people can justify their behavior,
they can bridge the gap between their own benefit gained
by the action and their view on themselves as being moral
persons. Accordingly, the different moral justifications of
PCE in EPs and IPs in our study might be explained by
the self-serving justification. Another possible explanation for
the different views EPs and IPs had on aspects related to
fairness might be that positive attitudes toward drugs do
correlate with the use of the drug, as Schelle et al. (2014)
summarize.
Furthermore, EPs in our study did not consider the positive
effects of PCE as being very strong. Although PCE might help
them focus better, they were aware that the drugs are not magic
potion that leads to outstanding results without still having to
work hard. In view of this, they did not perceive PCE as distorting
competition. In contrast, the IPs seemed to assume the effects
of PCE as being stronger than the EPs did. They believed that
users had found an easier method for gaining better results
than others who without PCE had to work harder for a good
performance. There clearly is a difference in the perception EPs
and IPs had of PCE effects. In fact, intra- and interpersonal
effects of PCE substances have been reported to vary (Husain
and Metha, 2011; Van der Schaaf et al., 2013). These variations
may explain part of the disorientation concerning the effects
of PCE, which may also influence moral perspectives on the
topic.
Reasons given for not using PCE or for not using PCE
any more were mainly health risks, in other words the
fear of harming oneself. This is interesting, since users in
general tend to rate PCE as less dangerous than non-users,
as Eickenhorst et al. (2012) found. Taking into account that
non-users rate the effects of PCE stronger than users, they
might also believe the health risks are higher, and may not
use PCE for that reason. To decide whether unwanted side
effects are worth the benefits is part of the decision for or
against the use of PCE (Maier and Schaub, 2015: p. 157).
The main moral reason given to not use PCE substances is
the fear of harming oneself and not the possible implications
on third persons. This aspect has been discussed in several
studies under the term “medical safety”: the more people were
concerned about aspects of medical safety, the more they tended
to object to substance use for PCE (Scheske and Schnall, 2012;
Santoni de Sio et al., 2016).
To summarize, in our small sample size that does not
allow generalization, fairness-related moral attitudes on
PCE differed considerably depending on whether or not the
interviewees were experienced with PCE. These results are in
line with similar studies. In particular, IPs considered issues
related to fairness as much more critical than EPs. Thus,
one’s view on PCE might not only depend on moral common
sense (like “using drugs is wrong,” “cheating is wrong”),
but also on having or not having used illegal/prescription
drugs for PCE before. While this may not seem totally
surprising, it points to the importance of including the
various relevant stakeholder groups in debates on the
ethical and social implications of PCE. In addition, as EPs
said their PCE use was primarily motivated by the wish
to “keep up” with others at school/university or at work,
it is advisable to further analyze working and studying
conditions and how these conditions affect individual’s
motivation and willingness to use illicit or prescription drugs
for PCE.
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